REFERENCES

1. Mondain M, Bordure P. Recommandations de Pratiques Cliniques (RPC) de la Société Française d’ORL et de Chirurgie Cervico-Faciale Prise en charge thérapeutique des OSM de l’enfant. 2016.
2. Triglia J-M, Roman S, Nicollas R. Otites séromuqueuses. J Pediatr Pueric. 2004;17(2):83–100.
3. Paradise JL. Otitis Media in Infants and Children. Pediatrics. 1980 May 1;65(5):917–43.
4. Knutsson J, Bagger-Sjöbäck D, von Unge M. Structural tympanic membrane changes in secretory otitis media and cholesteatoma. United States, Lippincott Williams & Wilkins; 2011.
5. Maw AR, Bawden R. Tympanic membrane atrophy, scarring, atelectasis and attic retraction in persistent, untreated otitis media with effusion and following ventilation tube insertion. Int J Pediatr Otorhinolaryngol. 1994;30(3):189–204.
6. Dornelles C de C, da Costa SS, Meurer L, Rosito LPS, da Silva AR, Alves SL. Comparison of acquired cholesteatoma between pediatric and adult patients. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol - Head Neck Surg. 2009 Oct;266(10):1553–61.
7. Knutsson J, Bagger-Sjöbäck D, von Unge M. Collagen type distribution in the healthy human tympanic membrane. United States, Lippincott Williams & Wilkins; 2009.
8. Ryding M, White P, Kalm O. Eustachian tube function and tympanic membrane findings after chronic secretory otitis media. Int J Pediatr Otorhinolaryngol. 2004;68(2):197–204.
9. Moon SK, Linthicum FH, Yang HD, Lee SJ, Park K. Activities of matrix metalloproteinases and tissue inhibitor of metalloproteinase-2 in idiopathic hemotympanum and otitis media with effusion. Acta Otolaryngol (Stockh). 2008 Feb;128(2):144–50.
10. Antonelli PJ, Schultz GS, Kim KM, Cantwell JS, Sundin DJ, Pemberton PA, et al. Alpha 1-antitrypsin and ilomastat inhibit inflammatory proteases present in human middle ear effusions. The Laryngoscope. 2003 Aug;113(8):1347–51.
11. Lauhio A, Rezes S, Tervahartiala T, Sziklai I, Pitkäranta A, Sorsa T. Matrix metalloproteinase-8/collagenase-2 in childhood otitis media with effusion. Ann Med. 2012 Feb;44(1):93–9.
12. Hassan F, Ren D, Zhang W, Gu X-X. Role of c-Jun N-terminal protein kinase 1/2 (JNK1/2) in macrophage-mediated MMP-9 production in response to Moraxella catarrhalis lipooligosaccharide (LOS). PloS One. 2012;7(5):e37912.
13. Fingleton B. Matrix metalloproteinases as regulators of inflammatory processes. BBA - Mol Cell Res. 2017;1864(11):2036–42.
14. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function 1 1 Dedicated to Professor H. Neurath on the occasion of his 90th birthday. Biochim Biophys Acta BBAProtein Struct Mol Enzymol. 2000;1477(1):267–83.
15. Granström G, Holmquist J, Jarlstedt J, Renvall U. Collagenase activity in middle ear effusions. Acta Otolaryngol (Stockh). 1985 Dec;100(5-6):405–13.
16. Juhn SK, Garvis WJ, Lees CJ, Le CT, Kim CS. Determining otitis media severity from middle ear fluid analysis. Ann Otol Rhinol Laryngol Suppl. 1994 May;163:43–5.
17. Sano S, Kamide Y, Schachern PA, Paparella MM. Micropathologic changes of pars tensa in children with otitis media with effusion. Arch Otolaryngol Head Neck Surg. 1994 Aug;120(8):815–9.
18. Sakakura K, Hamaguchi Y, Harada T, Yamagiwa M, Sakakura Y. Endotoxin and lysosomal protease activity in acute and chronic otitis media with effusion. Ann Otol Rhinol Laryngol. 1990 May;99(5 Pt 1):379–85.
19. Jennings CR, Guo L, Collins HM, Birchall JP. Matrix metalloproteinases 2 and 9 in otitis media with effusion. Clin Otolaryngol Allied Sci. 2001 Dec;26(6):491–4.
20. Jang C-H, Shin S-H, Cho H-H, Moon S-J, Cho Y-B. Expression of matrix metalloproteinase-9 and -2 in pediatric chronic otitis media with effusion. Int J Pediatr Otorhinolaryngol. 2006 Jul;70(7):1155–8.
21. Zielhuis GA, Haggard MP, Broek P van den. Long-term effects of otitis media with effusion: otomicroscopic findings. Am J Otol. 1995;16:365–72.